Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2398384 | 0.77 | OPRM1 (0.31) | OPRM1OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL2400134 | 0.76 | OPRM1 (0.33) | OPRM1OPRD1OPRK1 | |
| SCHEMBL2398395 | 0.74 | ALDH1A1 (0.44) | ALDH1A1OPRM1OPRD1OPRK1 | |
| SCHEMBL23514832 | 0.74 | OPRM1 (0.39) | OPRM1OPRD1OPRK1 | |
| SCHEMBL19567415 | 0.70 | TYK2 (0.31) | OPRM1OPRD1OPRK1 | |
| SCHEMBL19566796 | 0.70 | OPRM1 (0.33) | OPRM1OPRD1OPRK1 | |
| SCHEMBL23514873 | 0.69 | OPRM1 (0.38) | OPRM1OPRD1OPRK1 | |
| SCHEMBL12424458 | 0.69 | OPRM1 (0.38) | OPRM1OPRD1OPRK1 | |
| SCHEMBL25235628 | 0.68 | KDM1A (0.34) | OPRM1OPRD1OPRK1 | |
| SCHEMBL24868167 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663958-B1 | HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | VIROBAY INC (US) | 2015-02-25 | — | — | EP | disclosed |
| US-8013186-B2 | Haloalkyl containing compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-7737300-B2 | Processes and intermediates preparing cysteine protease inhibitors | VIROBAY, INC. (US) | 2010-06-15 | — | — | US | disclosed |
| US-7547701-B2 | Haloalkyl containing compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2009-06-16 | — | — | US | disclosed |
| US-20090023781-A1 | Haloalkyl Containing Compounds as Cysteine Protease Inhibitors | VIROBAY, INC. (US) | 2009-01-22 | — | — | US | disclosed |
| US-20080114175-A1 | Processes and Intermediates Preparing Cysteine Protease Inhibitors | QUEST DIAGNOSTICS INVESTMENTS LLC | 2008-05-15 | — | — | US | disclosed |
| EP-1817275-A1 | HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | Schering Aktiengesellschaft (DE) | 2007-08-15 | — | — | EP | disclosed |
| EP-1799645-A2 | PROCESSES AND INTERMEDIATES FOR PREPARING CYSTEINE PROTEASE INHIBITORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-06-27 | — | — | EP | disclosed |
| US-20060122184-A1 | Cyanomethyl derivatives as cysteine protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | US | disclosed |
| WO-2006060494-A1 | HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-06-08 | — | — | WO | disclosed |
| EP-1663958-A2 | HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2006034004-A2 | PROCESSES AND INTERMEDIATES FOR PREPARING CYSTEINE PROTEASE INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-03-30 | — | — | WO | disclosed |
| EP-1569954-A1 | CYANOMETHYL DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2005-09-07 | — | — | EP | disclosed |
| US-20050182096-A1 | Haloalkyl containing compounds as cysteine protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-08-18 | — | — | US | disclosed |
| WO-2005028429-A2 | HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
| WO-2004052921-A1 | CYANOMETHYL DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023781-A1 | Haloalkyl Containing Compounds as Cysteine Protease Inhibitors | CTSF, CTSS, CTSE | ALDH1A1 1944/4885OPRM1 4489/4885OPRD1 3680/4885 |
| US-20060122184-A1 | Cyanomethyl derivatives as cysteine protease inhibitors | CTSF, CTSB, CTSK | ALDH1A1 3662/4885OPRM1 4286/4885OPRD1 4216/4885 |
| US-20050182096-A1 | Haloalkyl containing compounds as cysteine protease inhibitors | CTSF, CTSS, CTSE | ALDH1A1 1944/4885OPRM1 4489/4885OPRD1 3680/4885 |
| US-20080114175-A1 | Processes and Intermediates Preparing Cysteine Protease Inhibitors | SPINT2, PREP, CPN1 | ALDH1A1 3526/4885OPRM1 4774/4885OPRD1 4466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.